Sign In
Buy AGIO
$27.68
+1.17 (+4.41%)
At Close: Jun 03, 2026
Agios Reports Business Highlights and Second Quarter 2021 Financial Results
07:00am, Thursday, 29'th Jul 2021
– Completed Regulatory Submissions for Mitapivat for the Treatment of Adults with Pyruvate Kinase (PK) Deficiency in the U.S. and EU –
Agios (AGIO) Files MAA in EU for Rare Genetic Disease Drug
12:09pm, Tuesday, 29'th Jun 2021
Agios Pharmaceuticals (AGIO) files a MAA in Europe for its most advanced drug, mitapivat, to treat adults with pyruvate kinase deficiency.
CAMBRIDGE, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetic
Agios (AGIO) Files NDA to FDA for Rare Disease Drug Mitapivat
12:47pm, Tuesday, 22'nd Jun 2021
Agios (AGIO) submits a new drug application to the FDA for its lead candidate, mitapivat, for treating adults with pyruvate kinase deficiency. Stock up.
Agios Launches myAgios® Patient Support Services for Pyruvate Kinase Deficiency
07:00am, Tuesday, 22'nd Jun 2021
CAMBRIDGE, Mass., June 22, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetic
Agios Pharma Files US Application For Mitapivat In PK Deficiency
11:07am, Monday, 21'st Jun 2021
Agios Pharmaceuticals Inc (NASDAQ: AGIO) has submitted an FDA marketing application seeking approval for mitapivat to treat adults with pyruvate kinase (PK) deficiency. The company says, if approve
Agios Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency
07:00am, Monday, 21'st Jun 2021
CAMBRIDGE, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetic
– Company Expects to File for Regulatory Approval for Mitapivat for the Treatment of Adults with PK Deficiency in the U.S. This Quarter and in the EU in Mid-2021 –
American Airlines, Biogen, Dow and More Thursday Afternoon Analyst Calls
12:12pm, Thursday, 10'th Jun 2021
With the trading day about halfway over, the markets were moving higher, after being stuck in the doldrums for the first half of the week.
– Agios to Host Investor Webcast on June 11 at 7:30 a.m. ET –
Agios' (AGIO) Q1 Earnings Miss, Pipeline Makes Progress
09:46am, Friday, 30'th Apr 2021
Agios (AGIO) incurs wider-than-expected loss in the first quarter of 2021. The company fails to record revenues due to the sale of its oncology portfolio including Tibsovo.
Agios Pharmaceuticals, Inc. (AGIO) CEO Jacqualyn Fouse on Q1 2021 Results - Earnings Call Transcript
12:26pm, Thursday, 29'th Apr 2021
Agios Pharmaceuticals, Inc. (AGIO) CEO Jacqualyn Fouse on Q1 2021 Results - Earnings Call Transcript
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Lags Revenue Estimates
10:31am, Thursday, 29'th Apr 2021
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -6.50% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
01:33pm, Thursday, 22'nd Apr 2021
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios to Webcast Conference Call of First Quarter 2021 Financial Results on April 29, 2021
07:00am, Thursday, 15'th Apr 2021
CAMBRIDGE, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat genetically defined diseases, today announced tha
